Vastcon has identified unique molecular signatures for metastatic cancers that provide critical insights into disease progression and prognosis. These insights provide the basis for new diagnostic tests and mechanisms of action for drug discovery and development.
Product Pipeline
Colorectal Cancer Screen
Metastatic Cancer Therapeutics
Colorectal Cancer Screen
Proprietary blood-based test for early detection of colorectal cancer, inlcluding precancerous lesions.
Breast Cancer Screen
Metastatic Cancer Therapeutics
Colorectal Cancer Screen
Proprietary simple IHC-based tests for assessing breast cancer prognosis and treatment response.
Metastatic Cancer Therapeutics
Metastatic Cancer Therapeutics
Metastatic Cancer Therapeutics
Therapeutics being pursued by VastCon subsidiary, Oncodrex (www.oncodrex.com).